BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Immunology - Molecular Biology

p100 Deficiency Is Insufficient for Full Activation of the Alternative NF-?B Pathway: TNF Cooperates with p52-RelB in Target Gene Transcription
Published: Monday, August 06, 2012
Author: Agnes Lovas et al.

by Agnes Lovas, Anja Weidemann, Daniela Albrecht, Lars Wiechert, Debra Weih, Falk Weih

Background

Constitutive activation of the alternative NF-?B pathway leads to marginal zone B cell expansion and disorganized spleen microarchitecture. Furthermore, uncontrolled alternative NF-?B signaling may result in the development and progression of cancer. Here, we focused on the question how does the constitutive alternative NF-?B signaling exert its effects in these malignant processes.

Methodology/Principal Findings

To explore the consequences of unrestricted alternative NF-?B activation on genome-wide transcription, we compared gene expression profiles of wild-type and NF-?B2/p100-deficient (p100-/-) primary mouse embryonic fibroblasts (MEFs) and spleens. Microarray experiments revealed only 73 differentially regulated genes in p100-/- vs. wild-type MEFs. Chromatin immunoprecipitation (ChIP) assays showed in p100-/- MEFs direct binding of p52 and RelB to the promoter of the Enpp2 gene encoding ENPP2/Autotaxin, a protein with an important role in lymphocyte homing and cell migration. Gene ontology analysis revealed upregulation of genes with anti-apoptotic/proliferative activity (Enpp2/Atx, Serpina3g, Traf1, Rrad), chemotactic/locomotory activity (Enpp2/Atx, Ccl8), and lymphocyte homing activity (Enpp2/Atx, Cd34). Most importantly, biochemical and gene expression analyses of MEFs and spleen, respectively, indicated a marked crosstalk between classical and alternative NF-?B pathways.

Conclusions/Significance

Our results show that p100 deficiency alone was insufficient for full induction of genes regulated by the alternative NF-?B pathway. Moreover, alternative NF-?B signaling strongly synergized both in vitro and in vivo with classical NF-?B activation, thereby extending the number of genes under the control of the p100 inhibitor of the alternative NF-?B signaling pathway.

  More...

 

//-->